M

Metagenomi Inc
NASDAQ:MGX

Watchlist Manager
Metagenomi Inc
NASDAQ:MGX
Watchlist
Price: 4.13 USD 1.98% Market Closed
Market Cap: 154.5m USD
Have any thoughts about
Metagenomi Inc?
Write Note

Metagenomi Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Metagenomi Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
M
Metagenomi Inc
NASDAQ:MGX
Other Liabilities
$80.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Liabilities
$33B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
28%
Gilead Sciences Inc
NASDAQ:GILD
Other Liabilities
$24.4B
CAGR 3-Years
63%
CAGR 5-Years
29%
CAGR 10-Years
39%
Amgen Inc
NASDAQ:AMGN
Other Liabilities
$4.5B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Liabilities
$2.5B
CAGR 3-Years
56%
CAGR 5-Years
50%
CAGR 10-Years
44%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Liabilities
$1.8B
CAGR 3-Years
35%
CAGR 5-Years
13%
CAGR 10-Years
23%
No Stocks Found

Metagenomi Inc
Glance View

Market Cap
154.6m USD
Industry
Biotechnology

Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

MGX Intrinsic Value
3.83 USD
Overvaluation 7%
Intrinsic Value
Price
M

See Also

What is Metagenomi Inc's Other Liabilities?
Other Liabilities
80.8m USD

Based on the financial report for Dec 31, 2023, Metagenomi Inc's Other Liabilities amounts to 80.8m USD.

What is Metagenomi Inc's Other Liabilities growth rate?
Other Liabilities CAGR 1Y
-14%

Over the last year, the Other Liabilities growth was -14%.

Back to Top